Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful hard but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination treatment in the healing of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the last several shares of mine. The first CytoDyn article of mine, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set away all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire job interview that I came away with an inadequate opinion of the company.

Irony of irony, the poor viewpoint of mine of the company has grown steadily, yet the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the expertise and associated intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) and also the first new drug program endorsement ($five million), as well as royalty payments of five percent of net sales upon commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to get a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and numerous indications, it’s this single therapy in addition to a “broad pipeline of indications” as it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

The opening banner of its on its site (below) shows an energetic organization with diverse interests albeit centered on leronlimab, several illness types, multiple publications and multiple presentations.

Might all this be smoke and mirrors? That’s a question I’ve been asking myself through the very start of my interest in this organization. Judging with the multiples of thousands of various commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *